Drug evaluation: AMG-531 for the treatment of thrombocytopenias

Curr Opin Investig Drugs. 2006 Sep;7(9):834-41.

Abstract

Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.

Publication types

  • Review

MeSH terms

  • Animals
  • Carrier Proteins / adverse effects*
  • Carrier Proteins / chemical synthesis
  • Carrier Proteins / metabolism
  • Carrier Proteins / pharmacokinetics
  • Carrier Proteins / pharmacology
  • Carrier Proteins / therapeutic use*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Humans
  • Quantitative Structure-Activity Relationship
  • Receptors, Fc / metabolism
  • Receptors, Fc / therapeutic use*
  • Recombinant Fusion Proteins
  • Thrombocytopenia / drug therapy*
  • Thrombopoietin

Substances

  • Carrier Proteins
  • Receptors, Fc
  • Recombinant Fusion Proteins
  • Thrombopoietin
  • romiplostim